Amgen, Wyeth To Fight Suit Over Aranesp, Enbrel

Law360, New York (February 27, 2009, 12:00 AM EST) -- A qui tam suit against Amgen Inc., Wyeth Pharmaceuticals Inc. and others over allegedly unlawful marketing activities in connection with Amgen's anemia drug Aranesp and the psoriasis and arthritis drug Enbrel, co-marketed by Wyeth, lacks merit and will be vigorously defended, Wyeth and Amgen said Monday.

Portions of a 60-count amended complaint, which named Amgen, Wyeth and several other defendants, were unsealed on Feb. 10 in the U.S. District Court for the District of Massachusetts, Wyeth said. Some of the document, including the name of the...
To view the full article, register now.